Enliven Therapeutics ELVN Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$23.63M+20.4% | -$29.67M-47.2% | -$20.15M+20.5% | -$25.34M+11.2% | -$28.54M-23.1% | ||
| $14K-69.6% | $46K-25.8% | $62K-23.5% | $81K+9.5% | $74K-7.5% | ||
| $7.4M-39.9% | $12.31M+71.3% | $7.19M-7.0% | $7.72M+13.6% | $6.8M+27.3% | ||
| —— | -$26.5K0.0% | -$26.5K0.0% | -$26.5K0.0% | -$26.5K-864% | ||
| -$519K-163% | $828K+181% | -$1.02M-229% | $789K+259% | $220K-31.9% | ||
| -$4.47M— | —— | —— | —— | -$2.5M-94.3% | ||
| -$97K-6.6% | -$91K-1.1% | -$90K-3.4% | -$87K-26.1% | -$69K+18.8% | ||
| -$19.29M-21.8% | -$15.84M-19.3% | -$13.28M+22.1% | -$17.06M+29.3% | -$24.13M-40.2% | ||
| $0— | —— | —— | $139K+595% | $20K— | ||
| —— | $53.25K0.0% | $53.25K0.0% | $53.25K0.0% | $53.25K— | ||
| $42.53M— | $0+100% | -$4.06M+97.8% | -$183.59M-12,965% | $1.43M— | ||
| $10.05M+1,804% | $528K+153% | $209K-84.2% | $1.32M+466% | $234K— | ||
| $10.05M+1,514% | $623K— | $0-100% | $218.38M+93,224% | $234K-99.4% | ||
| $33.29M+1,274% | -$2.84M+84.0% | -$17.71M— | —— | -$22.47M-196% | ||
| -$266K— | —— | $310K+525% | -$73K-262% | $45K+105% | ||
| $14K-69.6% | $46K-25.8% | $62K-23.5% | $81K+9.5% | $74K-7.5% | ||
| —— | -$26.5K0.0% | -$26.5K0.0% | -$26.5K0.0% | -$26.5K-864% | ||
| -$4.47M— | —— | —— | —— | -$2.5M-94.3% | ||
| -$97K-6.6% | -$91K-1.1% | -$90K-3.4% | -$87K-26.1% | -$69K+18.8% | ||
| -$1.65M-337% | $694K— | —— | $398K+162% | $152K— | ||
| $93K+1.1% | $92K+3.4% | $89K+2.3% | $87K+2.4% | $85K+4.9% | ||
| —— | $53.25K0.0% | $53.25K0.0% | $53.25K0.0% | $53.25K— | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| -$97K-6.6% | -$91K-1.1% | -$90K-3.4% | -$87K-26.1% | -$69K+18.8% | ||
| $0— | —— | —— | —— | $736K— | ||
| $658K— | —— | $0— | $0— | $0+100% | ||
| -$19.29M-21.8% | -$15.84M-19.3% | -$13.28M+22.8% | -$17.2M+28.8% | -$24.15M-40.4% | ||
| -$19.29M-21.8% | -$15.84M-19.3% | -$13.28M+22.8% | -$17.2M+28.8% | -$24.15M-40.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Enliven Therapeutics generate?
- Enliven Therapeutics (ELVN) generated -$65.5M in operating cash flow over the trailing twelve months.
- What is Enliven Therapeutics's free cash flow?
- After $159.0K of capital expenditures, Enliven Therapeutics's free cash flow was -$65.6M over the trailing twelve months, up 11.3% year over year.
- Where does Enliven Therapeutics's cash flow data come from?
- Every line is extracted from Enliven Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.